Page 60 - Read Online

Page 22 of 24 Saier et al. J Cancer Metastasis Treat 2021;7:43 https://dx.doi.org/10.20517/2394-4722.2021.87

immunity. Biology (Basel) 2020;9:434. DOI PubMed PMC
134. Montezuma MAP, Fonseca FP, Benites BM, et al. COX-2 as a determinant of lower disease-free survival for patients affected by
ameloblastoma. Pathol Res Pract 2018;214:907-13. DOI PubMed
135. Sun H, Zhang X, Sun D, et al. COX-2 expression in ovarian cancer: an updated meta-analysis. Oncotarget 2017;8:88152-62. DOI
PubMed PMC
136. Esbona K, Yi Y, Saha S, et al. The Presence of Cyclooxygenase 2, Tumor-Associated Macrophages, and Collagen Alignment as
Prognostic Markers for Invasive Breast Carcinoma Patients. Am J Pathol 2018;188:559-73. DOI PubMed PMC
137. Rothwell PM, Wilson M, Price JF, Belch JF, Meade TW, Mehta Z. Effect of daily aspirin on risk of cancer metastasis: a study of
incident cancers during randomised controlled trials. Lancet 2012;379:1591-601. DOI PubMed
138. Charalambous MP, Maihöfner C, Bhambra U, Lightfoot T, Gooderham NJ; Colorectal Cancer Study Group. Upregulation of
cyclooxygenase-2 is accompanied by increased expression of nuclear factor-kappa B and I kappa B kinase-alpha in human colorectal
cancer epithelial cells. Br J Cancer 2003;88:1598-604. DOI PubMed PMC
139. Harris RE. Cyclooxygenase-2 (cox-2) blockade in the chemoprevention of cancers of the colon, breast, prostate, and lung.
Inflammopharmacology 2009;17:55-67. DOI PubMed
140. Cui Y, Shu XO, Li HL, et al. Prospective study of urinary prostaglandin E2 metabolite and pancreatic cancer risk. Int J Cancer
2017;141:2423-9. DOI PubMed PMC
141. Miao J, Lu X, Hu Y, et al. Prostaglandin E(2) and PD-1 mediated inhibition of antitumor CTL responses in the human tumor
microenvironment. Oncotarget 2017;8:89802-10. DOI PubMed PMC
142. Hansen-Petrik MB, McEntee MF, Jull B, Shi H, Zemel MB, Whelan J. Prostaglandin E(2) protects intestinal tumors from
nonsteroidal anti-inflammatory drug-induced regression in Apc(Min/+) mice. Cancer Res 2002;62:403-8. PubMed
143. Myung SJ, Rerko RM, Yan M, et al. 15-Hydroxyprostaglandin dehydrogenase is an in vivo suppressor of colon tumorigenesis. Proc
Natl Acad Sci U S A 2006;103:12098-102. DOI PubMed PMC
144. Yan M, Myung SJ, Fink SP, et al. 15-Hydroxyprostaglandin dehydrogenase inactivation as a mechanism of resistance to celecoxib
chemoprevention of colon tumors. Proc Natl Acad Sci U S A 2009;106:9409-13. DOI PubMed PMC
145. Nakanishi M, Menoret A, Tanaka T, et al. Selective PGE(2) suppression inhibits colon carcinogenesis and modifies local mucosal
immunity. Cancer Prev Res (Phila) 2011;4:1198-208. DOI PubMed PMC
146. Howe LR, Subbaramaiah K, Kent CV, et al. Genetic deletion of microsomal prostaglandin E synthase-1 suppresses mouse mammary
tumor growth and angiogenesis. Prostaglandins Other Lipid Mediat 2013;106:99-105. DOI PubMed PMC
147. O'Callaghan G, Houston A. Prostaglandin E2 and the EP receptors in malignancy: possible therapeutic targets? Br J Pharmacol
2015;172:5239-50. DOI PubMed PMC
148. Uluçkan O, Eagleton MC, Floyd DH, et al. APT102, a novel adpase, cooperates with aspirin to disrupt bone metastasis in mice. J Cell
Biochem 2008;104:1311-23. DOI PubMed PMC
149. Inada M, Takita M, Yokoyama S, et al. Direct Melanoma Cell Contact Induces Stromal Cell Autocrine Prostaglandin E2-EP4
Receptor Signaling That Drives Tumor Growth, Angiogenesis, and Metastasis. J Biol Chem 2015;290:29781-93. DOI PubMed
PMC
150. Hiraga T, Myoui A, Choi ME, Yoshikawa H, Yoneda T. Stimulation of cyclooxygenase-2 expression by bone-derived transforming
growth factor-beta enhances bone metastases in breast cancer. Cancer Res 2006;66:2067-73. DOI PubMed
151. Singh B, Berry JA, Shoher A, Lucci A. COX-2 induces IL-11 production in human breast cancer cells. J Surg Res 2006;131:267-75.
DOI PubMed
152. Singh B, Berry JA, Vincent LE, Lucci A. Involvement of IL-8 in COX-2-mediated bone metastases from breast cancer. J Surg Res
2006;134:44-51. DOI PubMed
153. Xu S, Zhou W, Ge J, Zhang Z. Prostaglandin E2 receptor EP4 is involved in the cell growth and invasion of prostate cancer via the
cAMPPKA/PI3KAkt signaling pathway. Mol Med Rep 2018;17:4702-12. DOI PubMed
154. Karavitis J, Zhang M. COX2 regulation of breast cancer bone metastasis. Oncoimmunology 2013;2:e23129. DOI PubMed PMC
155. Singh B, Berry JA, Shoher A, Ayers GD, Wei C, Lucci A. COX-2 involvement in breast cancer metastasis to bone. Oncogene
2007;26:3789-96. DOI PubMed
156. Watanabe K, Tominari T, Hirata M, et al. Abrogation of prostaglandin E-EP4 signaling in osteoblasts prevents the bone destruction
induced by human prostate cancer metastases. Biochem Biophys Res Commun 2016;478:154-61. DOI PubMed
157. Gupta S, Srivastava M, Ahmad N, Sakamoto K, Bostwick DG, Mukhtar H. Lipoxygenase-5 is overexpressed in prostate
adenocarcinoma. Cancer 2001;91:737-43. DOI PubMed
158. Knab LM, Grippo PJ, Bentrem DJ. Involvement of eicosanoids in the pathogenesis of pancreatic cancer: the roles of cyclooxygenase-
2 and 5-lipoxygenase. World J Gastroenterol 2014;20:10729-39. DOI PubMed PMC
159. Yoshimura R, Matsuyama M, Tsuchida K, Kawahito Y, Sano H, Nakatani T. Expression of lipoxygenase in human bladder
carcinoma and growth inhibition by its inhibitors. J Urol 2003;170:1994-9. DOI PubMed
160. Hoque A, Lippman SM, Wu TT, et al. Increased 5-lipoxygenase expression and induction of apoptosis by its inhibitors in esophageal
cancer: a potential target for prevention. Carcinogenesis 2005;26:785-91. DOI PubMed
161. Matsuyama M, Yoshimura R, Mitsuhashi M, et al. 5-Lipoxygenase inhibitors attenuate growth of human renal cell carcinoma and
induce apoptosis through arachidonic acid pathway. Oncol Rep 2005;14:73-9. PubMed
162. Steinhilber D, Fischer AS, Metzner J, et al. 5-lipoxygenase: underappreciated role of a pro-inflammatory enzyme in tumorigenesis.
Front Pharmacol 2010;1:143. DOI PubMed PMC
163. Magnusson C, Ehrnström R, Olsen J, Sjölander A. An increased expression of cysteinyl leukotriene 2 receptor in colorectal